Clinical trials: Respiratory Infection
Pulmonary Sarcoidosis, Lung Function
Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
Sarcoidosis is a granulomatous disease for which the molecular and immunologic association with mycobacteria continues to strengthen.
- Trial name
- CLEAR Lung (NCT01169038)
- Testing
- levaquin; ethambutol; rifampin and azithromycin.
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University
Breast Cancer Related Lymphedema, Covid19
Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery.
- Trial name
- LymphVAX (NCT04872738)
- Testing
- Survey
- Where
- United States
- Volunteers
- 714 people
- Sponsor
- Massachusetts General Hospital
Non-allergic Rhinitis
The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population
The purpose of this study to determine the therapeutic response of non-allergic rhinitis patients that have been subtyped as non-allergic rhinitis with local IgE elevation or non-allergic rhinopathy to intranasal capsaicin based…
- Trial name
- NCT05093478
- Testing
- Intranasal capsaicin, topical lidocaine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center, Houston
Covid19
Dräger COVID-19 Antigen Test Clinical Performance Study
The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2 detection in clinical nasal specimens.
- Trial name
- NCT04698993
- Testing
- Dräger Antigen Test SARS-CoV-2
- Where
- Germany
- Volunteers
- 388 people
- Sponsor
- Drägerwerk AG & Co. KGaA
COVID-19
Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
This is a randomized, double-blind, placebo-controlled, superiority phase IIa trial to assess the safety and efficacy of dupilumab use in hospitalized patients with moderate to severe COVID-19 infection.
- Trial name
- SafeDrop (NCT04920916)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Healthy
Assessing Choice in the Employer Setting (ACES) Study
The purpose of this study is to determine, among adults and in the total population, the effects of offering a choice of FluMist or trivalent inactivated vaccine (TIV) in the employer setting when compared to a control group.
- Trial name
- MA181 (NCT00808808)
- Testing
- Choice of TIV or FluMist with baseline advertisement, Choice of TIV or FluMist with enhanced advertisement and incentives, Control - Usual care offering TIV only with baseline advertisement
- Where
- 47 sites in United States
- Volunteers
- 4,411 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Flu
FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care
Adjuvanted flu vaccine, Fluad, is not immunologically inferior to HD influenza vaccine in older persons living in long-term care.
- Trial name
- NCT03694808
- Testing
- Fluad Vaccine, Fluzone HD Vaccine
- Where
- 2 sites in United States
- Volunteers
- 478 people
- Sponsor
- David H. Canaday
Influenza
Influenza Vaccine in Pregnant Women
In pregnant women, flu may cause complications like pneumonia (infection of the lungs) or hospitalization. In the United States (US) it is recommend that all women get flu vaccine if they are going to be pregnant or deliver…
- Trial name
- NCT00905125
- Testing
- Fluzone®, Fluarix®
- Where
- 9 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Pilot Trial of XFBD, a TCM, in Persons With COVID-19
The purpose of this study is to document the safety of taking traditional Chinese medicine (TCM) in patients with COVID-19 and to gain information to determine whether a study with TCM can be conducted.
- Trial name
- NCT04810689
- Testing
- Xuanfei Baidu Granules
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Darcy Spicer
Pneumonia, Bacterial
A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
The purpose of this study is to test if intravenous sulopenem and an oral drug, PF-03709270 are safe and effective in patients that are hospitalized with community acquired pneumonia.
- Trial name
- NCT00797108
- Testing
- sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 35 people
- Sponsor
- Pfizer
Cross Infection, Pneumonia, Ventilator-associated
Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit
This prospective, randomized, controlled trial will compare the incidence of nosocomial infections (composite of primary bloodstream infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and…
- Conditions
- Cross Infection, Pneumonia, Ventilator-associated, Catheter-related Infections, Infection Due to Indwelling Urinary Catheter
- Trial name
- NCT01640925
- Testing
- Chlorhexidine gluconate, Standard bathing
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Joshua Swan
COVID-19, SARS-CoV 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT04358068
- Testing
- Hydroxychloroquine (HCQ), Azithromycin (Azithro)
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Respiratory Infection
Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI
The purpose of this study is is to demonstrate superiority of Polyoxidonium, nasal and sublingual spray, 6 mg/ml over placebo in children aged from 1 to 12 years with acute respiratory viral infections.
- Trial name
- NCT03840135
- Testing
- Polyoxidonium 6 mg/ml
- Where
- 11 sites in Russia
- Volunteers
- 172 people
- Sponsor
- NPO Petrovax
Acellular Pertussis, Tetanus
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.
The purpose of this study is to assess the efficacy and safety of repeating dTpa booster in adults 10 years after previous booster vaccination with dTpa in a prior clinical study.
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00610168
- Testing
- Boostrix TM
- Where
- Finland
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD, Chronic Bronchitis
N-Acetylcysteine for Patients With COPD and Chronic Bronchitis
N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is widely prescribed for patients with chronic obstructive lung disease (COPD), particularly for those who have accompanying symptoms of…
- Trial name
- NCT01739790
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Minnesota
COVID-19
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if a high dose of Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19…
- Trial name
- NCT04480424
- Testing
- GAMUNEX-C, Standard Medical Treatment
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Grifols Therapeutics LLC
SARS-CoV-2 Infection, COVID-19
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 (molnupiravir) versus placebo as measured by SARS-CoV-2 viral RNA…
- Trial name
- NCT04405570
- Testing
- Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg
- Where
- 10 sites in United States
- Volunteers
- 204 people
- Sponsor
- Ridgeback Biotherapeutics, LP
Rhinoconjunctivitis, Rhinitis
Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00562159
- Testing
- SCH 697243, Loratadine 10 mg Rescue Treatment, Olopatadine 0.1% Rescue Treatment
- Volunteers
- 439 people
- Sponsor
- ALK-Abelló A/S
COVID-19
BERRY- a Study of Sambucol ® in the Treatment, and Reduction of Symptoms in Participants With Coronavirus 19
Severe acute respiratory syndrome (SARS) coronavirus 2 (CoV 2) (COVID19) is a readily transmissible virus that has a wide ranging incubation period of 2-14 days. The symptoms include fever, cough and loss of taste and smell.
- Trial name
- BERRY (NCT05489770)
- Testing
- Sambucol® Black Elderberry Original (Sambucus nigra) Liquid
- Where
- United Kingdom
- Volunteers
- 204 people
- Sponsor
- East Kent Hospitals University NHS Foundation Trust
Respiratory Syncytial Virus Infection
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants.
- Trial name
- CLEVER (NCT04767373)
- Testing
- Clesrovimab
- Where
- 217 sites in United States, Argentina and 22 more
- Volunteers
- 3,632 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.